In most cases, health insurance does cover hormone replacement therapy when a doctor documents that it is medically necessary, but the answer to “does insurance cover HRT” depends on your plan type, your diagnosis, and which specific medication your provider prescribes. Marketplace plans, Medicare Part D, employer plans, and many state Medicaid programs all include FDA-approved hormones like estradiol and testosterone on their drug lists. What varies is the paperwork required to approve the prescription and the tier that decides your copay.
What Insurers Require Before They Pay
Coverage hinges on a formal diagnosis. Your provider submits an ICD-10 billing code with the claim: E28.3 for primary ovarian failure, E29.1 for testicular hypofunction, or HA60 (formerly F64.0) for gender incongruence are common examples. The code tells the insurer why the treatment is clinically warranted.
Most carriers also want laboratory evidence of a hormone deficiency or a related condition. For testosterone therapy, Medicare’s coverage rule requires two separate fasting blood draws taken before 10:00 a.m. on different days, both showing low levels, plus a recent prostate-specific antigen test, a digital prostate exam, and a hematocrit evaluation.1Centers for Medicare & Medicaid Services. LCD – Treatment of Males With Low Testosterone If the initial total testosterone is below 280 ng/mL, further testing is warranted. Private insurers tend to apply similar thresholds.
For gender-affirming hormone therapy, insurers that cover these treatments may ask for a letter from a licensed physician or mental health professional outlining the clinical rationale, treatment history, and care plan. Requirements vary carrier by carrier, so it is worth checking your plan documents before your first prescription is written.
How Your Plan Type Changes the Answer
Marketplace and Individual Plans
Plans sold through the federal or state marketplaces, and most individual and small-group plans sold outside them, must cover prescription drugs as one of ten essential health benefits under the Affordable Care Act. Each plan must cover at least the same number of drugs in every therapeutic class as the state’s benchmark plan.2CMS. Information on Essential Health Benefits (EHB) Benchmark Plans In practice, oral estradiol tablets, testosterone gels, transdermal patches, and injectables appear on most marketplace formularies. The specific products and tiers differ by plan, and listing is not the same as automatic approval; prior authorization and generic-first rules are common.
Medicare Part D
Part D covers FDA-approved hormones prescribed for a medically accepted indication. Generic estradiol tablets usually sit on the lowest-cost tier, while brand-name patches, vaginal rings, and specialty formulations land higher.3Medicare. How Do Drug Plans Work Quantity limits apply to some estradiol patches and vaginal tablets, and higher-cost formulations may require prior authorization. Medicare also covers hormone therapy for gender dysphoria when the patient can make an informed decision to engage in treatment. Comparing formularies during open enrollment can make a real difference to what you pay.
Employer Plans: Fully Insured vs. Self-Funded
If you get coverage through work, how the plan is funded controls which rules apply. A fully insured plan, where the employer buys a policy from an insurance company, follows the insurance laws of the state where the policy is issued. A self-funded plan, where the employer pays claims directly from company assets, is governed primarily by the federal Employee Retirement Income Security Act of 1974 (ERISA), which preempts state insurance mandates.
This matters for HRT. Someone living in a state with strong hormone coverage requirements can still face an exclusion if the employer self-funds the plan. More than half of workers with employer coverage are in self-funded arrangements. Your Summary Plan Description, which your employer or plan administrator must provide, will tell you which type you have.
State Mandates and Federal Nondiscrimination Rules
A growing number of states require fully insured plans to cover gender-affirming care, including hormone therapy, and prohibit blanket exclusions for transition-related treatments. The number of states and the scope of each mandate continue to shift.
At the federal level, Section 1557 of the Affordable Care Act bars sex discrimination in health programs that receive federal funding, including hospitals that take Medicare and insurers that participate in the marketplace.4HHS.gov. Section 1557 – Protecting Individuals Against Sex Discrimination A 2024 HHS rule interpreted this to include gender identity, but federal courts blocked those provisions through nationwide injunctions, a federal district court permanently vacated them in October 2025, and HHS rescinded related guidance in February 2025.5HHS.gov. Rescission of HHS Notice and Guidance on Gender Affirming Care For now, state mandates offer the strongest legal protection for gender-affirming hormone coverage in fully insured plans. Your state insurance commissioner’s office can tell you what applies in your jurisdiction.
What You Actually Pay at the Pharmacy
Coverage is only half the picture. Your cost at pickup depends on where the medication sits on your plan’s formulary. Insurers organize covered drugs into tiers, each with its own copay or coinsurance.3Medicare. How Do Drug Plans Work
- Tier 1, the lowest cost, typically holds generics such as generic estradiol tablets or generic testosterone cypionate for injection.
- Tier 2 covers preferred brand-name drugs, including some transdermal estradiol patches and testosterone gels.
- Tier 3 holds non-preferred brand-name drugs that have a lower-cost alternative available on a lower tier.
- The specialty tier carries the highest cost and may include certain vaginal rings or complex formulations.
Delivery method matters. A self-administered injectable testosterone vial often costs far less through insurance than a brand-name daily gel or patch delivering the same hormone. If your doctor prescribes a higher-tier option, your insurer may require step therapy, meaning you try a lower-tier alternative first.
Prior authorization is the other common gate. Your doctor sends paperwork showing you meet the clinical criteria, and insurers typically respond within five to ten business days with an approval, a denial, or a suggested lower-cost alternative.
Forms of HRT Insurance Usually Will Not Cover
Three categories tend to be excluded even on plans that otherwise cover hormone therapy.
- Hormones prescribed for anti-aging, longevity, or general wellness without a diagnosed deficiency. Testosterone or growth hormone written for energy, libido, or cosmetic reasons alone will likely be denied.
- Pharmacy-compounded bioidentical hormones, which are custom-mixed and have not gone through FDA testing for safety or efficacy. Most insurers either exclude compounded hormones entirely or cover them only when no FDA-approved equivalent exists.6VA.gov. Compounded Bioidentical Hormone Therapy
- Subcutaneous hormone pellets, which many insurers classify as investigational. No FDA-approved commercial estradiol pellet exists in the United States, and concerns about unpredictable hormone levels and difficulty reversing treatment lead to coverage denials.
If one of these is what your provider recommends, ask whether an FDA-approved alternative would achieve the same clinical goal. Switching from a compounded cream to an approved transdermal patch, for example, can turn a denial into a covered prescription.
If Your Claim Is Denied
You have a legal right to appeal a denied HRT claim, and federal timelines govern the process.7HealthCare.gov. Appealing a Health Plan Decision
Internal Appeal
File within 180 days of receiving the denial notice.8HealthCare.gov. Internal Appeals The insurer must conduct a full and fair review using staff who were not involved in the original decision, and issue a ruling within 30 days for care you have not yet received or 60 days for services already provided.9CMS. Appealing Health Plan Decisions
External Review
If the internal appeal fails, request an external review by an independent third party. That reviewer is not affiliated with your insurance company, and their decision binds the insurer.
Expedited Appeals
When waiting could seriously jeopardize your health, you can request expedited review. Both internal and external appeals must then be decided within 72 hours, and you can run them simultaneously rather than finishing the internal process first. You can start an expedited appeal orally, though the insurer must follow up with a written decision within three days.10HHS.gov. Internal Claims and Appeals and the External Review Process Overview
A Note on Medicaid for Minors
In December 2025, CMS published a proposed rule that would prohibit federal Medicaid and CHIP funding for what the rule calls “sex-rejecting procedures” provided to patients under 18 (under 19 for separate CHIP programs), with a proposed effective date of October 1, 2026.11Federal Register. Medicaid Program – Prohibition on Federal Medicaid and CHIP Funding for Sex-Rejecting Procedures Furnished to Children The prohibition would cover pharmaceutical interventions to suppress puberty or align physical characteristics with a gender identity differing from a minor’s sex. It would not touch mental health counseling for gender dysphoria, treatment for medically verifiable disorders of sexual development, or care for complications from prior procedures, and states could still fund these services with state-only dollars. Because the rule is proposed rather than final, its scope and timing could change. Adult Medicaid coverage for hormone therapy is not affected by the proposal.